Zobrazeno 1 - 10
of 322
pro vyhledávání: '"Gallia G"'
Autor:
Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Bleeding in people with hemophilia A can be life threatening, and intra‐articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated with coagulation factor(s) (untreated b
Externí odkaz:
https://doaj.org/article/e0003f2e961e49a1b507a404d3f16f57
Autor:
Callaghan, Michael U. *, Asikanius, Elina, Lehle, Michaela, Oldenburg, Johannes, Mahlangu, Johnny, Uguen, Marianne, Chebon, Sammy, Kruse‐Jarres, Rebecca, Jiménez‐Yuste, Víctor, Shima, Midori, Trask, Peter, Kempton, Christine L., Kessler, Craig M., Levy, Gallia G., Peyvandi, Flora
Publikováno v:
In Research and Practice in Thrombosis and Haemostasis August 2022 6(6)
Autor:
Callaghan, Michael U. *, Negrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Howard, Monet, Bienz, Nives Selak, Shima, Midori, Jiménez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia G., Pipe, Steven W., Oldenburg, Johannes
Publikováno v:
In Blood 22 April 2021 137(16):2231-2242
Autor:
Lu, Genmin, Conley, Pamela B., Leeds, Janet M., Karbarz, Mark J., Levy, Gallia G., Mathur, Vandana S., Castillo, Janice, Crowther, Mark, Curnutte, John T.
Publikováno v:
In Blood Advances 25 February 2020 4(4):728-739
Autor:
Young, Guy 1, Liesner, Ri 2, Chang, Tiffany 3, Sidonio, Robert, Jr 4, Oldenburg, Johannes 5, Jiménez-Yuste, Victor 6, Mahlangu, Johnny 7, Kruse-Jarres, Rebecca 8, Wang, Michael 9, Uguen, Marianne 10, Doral, Michelle Y. 3, Wright, Lilyan Y. 3, Schmitt, Christophe 10, Levy, Gallia G. 3, Shima, Midori 11, Mancuso, Maria Elisa 12
Publikováno v:
In Blood 12 December 2019 134(24):2127-2138
Autor:
Levy, Gallia G. *, Asikanius, Elina, Kuebler, Peter, Benchikh El Fegoun, Soraya, Esbjerg, Sille, Seremetis, Stephanie
Publikováno v:
In Journal of Thrombosis and Haemostasis September 2019 17(9):1470-1477
Autor:
Pipe, Steven W, Shima, Midori, Lehle, Michaela, Shapiro, Amy, Chebon, Sammy, Fukutake, Katsuyuki, Key, Nigel S, Portron, Agnès, Schmitt, Christophe, Podolak-Dawidziak, Maria, Selak Bienz, Nives, Hermans, Cedric, Campinha-Bacote, Avrita, Kiialainen, Anna, Peerlinck, Kathelijne, Levy, Gallia G, Jiménez-Yuste, Victor
Publikováno v:
In The Lancet Haematology June 2019 6(6):e295-e305
Autor:
Ellies, Lesley G., Ditto, David, Levy, Gallia G., Wahrenbrock, Mark, Ginsburg, David, Varki, Ajit, Le, Dzung T., Marth, Jamey D.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 2002 Jul . 99(15), 10042-10047.
Externí odkaz:
https://www.jstor.org/stable/3059331
Autor:
Christophe Schmitt, Koichiro Yoneyama, Gallia G. Levy, Sayaka Nagami, Tiffany Chang, Claire Petry, Christophe Dhalluin
Publikováno v:
The Journal of Clinical Pharmacology. 62:232-244
Emicizumab is a bispecific antibody mimicking the cofactor function of activated coagulation factor VIII to prevent bleeds in patients with hemophilia A. The dose selection for the first-in-child phase III study of emicizumab was addressed by pediatr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df582b146a367f57b8ee9323e5f53523
https://doi.org/10.1002/jcph.1968
https://doi.org/10.1002/jcph.1968
Autor:
Amy D. Shapiro, Sylvia von Mackensen, Michael U. Callaghan, Ido Paz-Priel, Midori Shima, Steven W. Pipe, Víctor Jiménez-Yuste, Claude Negrier, Gallia G. Levy, Markus Niggli, Johnny Mahlangu, Sammy Chebon, Avrita Campinha-Bacote, Mark W. Skinner, Michaela Lehle, Johannes Oldenburg
Publikováno v:
Haemophilia
Introduction Severe haemophilia A (HA) has a major impact on health‐related quality of life (HRQoL). Aim Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b187485c94a41adafcf8090c856810f
https://doi.org/10.1111/hae.14363
https://doi.org/10.1111/hae.14363